ARTICLE | Clinical News

Riferminogen pecaplasmid: Phase III data

September 27, 2010 7:00 AM UTC

In the double-blind, international Phase III TAMARIS trial in 525 patients with CLI and skin lesions who were not eligible for revascularization, intramuscular NV1FGF every 2 weeks over a 6-week period missed the primary endpoint of superiority to placebo in preventing major amputation or death from any cause over 12 months. sanofi said it is evaluating all options for NV1FGF development. Final data will be presented at the American Heart Association meeting in Chicago in November. ...